Compare FFIC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | OABI |
|---|---|---|
| Founded | 1929 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 237.4M |
| IPO Year | 1996 | N/A |
| Metric | FFIC | OABI |
|---|---|---|
| Price | $15.98 | $2.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.80 | $4.50 |
| AVG Volume (30 Days) | 193.4K | ★ 712.9K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 151.43 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $7,455,000.00 | N/A |
| Revenue This Year | $14.57 | $52.42 |
| Revenue Next Year | $6.64 | $64.69 |
| P/E Ratio | $93.76 | ★ N/A |
| Revenue Growth | ★ 7.31 | N/A |
| 52 Week Low | $11.13 | $1.22 |
| 52 Week High | $17.79 | $2.61 |
| Indicator | FFIC | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 87.04 |
| Support Level | $15.56 | $1.43 |
| Resistance Level | $16.58 | N/A |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 61.83 | 98.19 |
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.